Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Segal E, Zhang F, Lin X, King G, Shalem O, Shilo S, et al. Building an international consortium for tracking coronavirus health status. Nat Med. 2020;26(8):1161-1165.

Cagino K, Levitan D, Schatz-Siemers N, Zarnegar R, Chapman-Davis E, Holcomb K, et al. Multiple malignant transformations of an ovarian mature cystic teratoma. Ecancermedicalscience. 2020;14:1009.

Sepulveda J, Westblade LF, Whittier S, Satlin MJ, Greendyke WG, Aaron JG, et al. Bacteremia and Blood Culture Utilization during COVID-19 Surge in New York City. J Clin Microbiol. 2020;58(8).

Showalter K, Magro C, Zhang Y, Spiera R, Orange DE, Gordon JK. Response to: 'Correspondence on 'Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement'' by Manetti. Ann Rheum Dis. 2020.

Herbst RS, Aisner DL, Sonett JR, Turk AT, Weintraub JL, Lindeman NI. Practical Considerations Relating to Routine Clinical Biomarker Testing for Non-small Cell Lung Cancer: Focus on Testing for RET Fusions. Front Med (Lausanne). 2020;7:562480.

Bander ED, Kocharian G, Liechty B, Tsiouris AJ, Schwartz TH. Spontaneous regression of a clival chordoma. Case report. Acta Neurochir (Wien). 2020;162(2):433-436.

Schwartz Z, Magro CM. Intralesional overlap syndrome: Sclerodermic lupus panniculitis and sclerodermic discoid lupus erythematosus. JAAD Case Rep. 2020;6(3):166-168.

Fiore D, Cappelli LV, Broccoli A, Zinzani PL, Chan WC, Inghirami G. Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer. 2020;20(6):323-342.

Patel N, Cricco-Lizza E, Kasabwala K, Xu C, Robinson BD, Khani F, et al. Corrigendum to 'The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy' [European Urology Oncology 1 (2018) 263-267]. Eur Urol Oncol. 2020;3(3):394.

Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, et al. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020;10(3):440-459.